Parmax Pharma Limited

BSE: 540359
Parmax Pharma Limited - pharma in Hadamtala, Gujarat, India. FY 2026 financials and compliance.
CIN L24231GJ1994PLC023504 Incorporated 02 November 1994 ROC Ahmedabad HQ Hadamtala, Gujarat, India
Active Listed - BSE: 540359 Public Limited Company pharma
Data last updated
Revenue · FY 2026
₹12.11 Cr
▼ 57.06% YoY
Computed EBITDA · FY 2026
-₹3.59 Cr
▼ 1321.01% YoY
Net profit · FY 2026
-₹4.16 Cr
▼ 98.62% YoY
Authorised capital
₹6 Cr
Registered with MCA
Paid-up capital
₹3.74 Cr
Issued & subscribed
Open charges
₹8.4 Cr
Satisfied ₹14.96 Cr
Company age
32 yrs
Est. 1994
Employees · EPFO
9
Latest available

About Parmax Pharma Limited

Data last updated: 11 January 2026

Parmax Pharma Limited is a public limited company based in Hadamtala, Gujarat, India. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 02 November 1994, the company has been in operation for over 32 years.

Registered with ROC Ahmedabad under CIN L24231GJ1994PLC023504. Listed on BSE: 540359.

Capital: an authorised share capital of ₹6 Cr and a paid-up capital of ₹3.74 Cr. It is led by directors including Ami Shah Rajeshbhai and Umang Alkesh Gosalia.

Last AGM: 30 September 2024. Financial statements filed for year ended 31 March 2024. Office: Plot No. 20 Survey No. 52 Rajkot – Gondal National Highway No. 27, Hadamtala, Gujarat, India – 360311.

As per BSE-filed standalone financials for FY 2026, the company reported a revenue of ₹12.11 Cr, a decline of 57.06% compared to the previous year. Total assets are valued at ₹28.05 Cr (up 49.6% YoY).

The company has a workforce of approximately 9 employees as per the latest available data.

The company is associated with 1 brand - Parmax Pharma. As per MCA filings, the company has open charges of ₹8.4 Cr and satisfied charges of ₹14.96 Cr on record.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website parmaxpharma.com.

Company Details of Parmax Pharma Limited
CIN L24231GJ1994PLC023504
Registration Number 023504
Incorporation Date 02 November 1994
ROC Ahmedabad
Listing Status Listed (BSE: 540359)
Company Status Active
Date of Last AGM 30 September 2024
Date of Balance Sheet 31 March 2024
Compliance Status Active Compliant
Key People
Umang Alkesh Gosalia Managing Director Ami Shah Rajeshbhai Director Nikhil Sureshchandra Uchat Director
Contact Details
  • Email
    Locked
  • Telephone
    Locked
  • Website
    parmaxpharma.com
  • Social Media
    Locked
  • Registered Address
    Plot No. 20 Survey No. 52 Rajkot – Gondal National Highway No. 27, Hadamtala, Gujarat, India – 360311
  • Industry
    Pharma, Drug Formulation & Development
Company report
Parmax Pharma Limited - full intelligence report
  • Historical Financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Litigation, compliance and MCA filings
  • PDF report delivered after checkout
₹799 ₹999 20% off
Secure checkout · GST invoice included

Unlock the full Parmax Pharma Limited report

Financials, compliance, directors, charges, ownership and filings for Parmax Pharma Limited in one report.

10-year financials Directors & ownership Charges & compliance

Associated Brands with Parmax Pharma Limited

Parmax Pharma Limited operates one associated brand: Parmax Pharma. These brands represent Parmax Pharma Limited's diversified market presence and brand portfolio.

Brand Description Website
Parmax Pharma
Parmax Pharma Ltd is a pharmaceutical company that manufactures and sells bulk drugs, drugs intermediates, and specialty chemicals, with a focus on leveraging its scientific expertise and strong manufacturing capabilities to drive growth and profitability. parmaxpharma.com

Competitors & Alternatives of Parmax Pharma Limited

Brands and companies operating in the same space as Parmax Pharma Limited include Laurus Labs, Symbiotec, Beijing Biostar Technologies and 6 more.

Competitor Description Location Founded
Laurus Labs Laurus Labs Pharmaceutical and biotechnology company Hyderabad, India, India 2005
Symbiotec Symbiotec Non-sterile steroid hormone-based APIs and intermediates are manufactured. Indore, India, India 2002
Beijing Biostar Technologies Beijing Biostar Technologies APIs, intermediates, and biochemical reagents are developed and manufactured. Beijing, China, China 2002
Sterling Pharma Solutions Sterling Pharma Solutions Contract development, manufacturing, and analytical services for APIs are offered. Dudley, United Kingdom, United Kingdom 2016
Provepharm Life Solutions Provepharm Life Solutions APIs and drug products are developed and valorized in pharmaceuticals. Marseille, France, France 1998
Hikal Hikal APIs and intermediates are produced via custom synthesis and research. Mumbai, India, India 1988
Snapdragon Chemistry Snapdragon Chemistry Drug discovery and development service provider Cambridge, United States, United States 2014
SeQuent SeQuent APIs are developed and manufactured for therapeutic areas. Bengaluru, India, India 2002
Jubilant Pharma Jubilant Pharma Pharmaceuticals, APIs, and radiopharmaceuticals are manufactured by the company. Noida, India, India 1978

Business Activity of Parmax Pharma Limited

Parmax Pharma Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main Activity Group Code Description of Main Activity Business Activity Code Description of Business Activity Turnover Percentage
C Manufacturing C6 Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products Locked
Premium access

Business activity turnover details for Parmax Pharma Limited

Turnover contribution percentages and historical activity changes require an active report plan.

  • Turnover contribution
  • Historical classifications
  • Filing-level activity changes

Verified entity values are shown only after access is granted.

Auditor Details of Parmax Pharma Limited

Parmax Pharma Limited is audited by B A SHAH S R MEHTA AND CO (ICAI peer reviewed, certificate valid till 2027-05-31) for the financial year 2026, as reported in its BSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.

Name Financial year Audit opinion
B A SHAH S R MEHTA AND CO (ICAI peer reviewed, certificate valid till 2027-05-31) FY 2026 Declaration of unmodified opinion

Board of Directors of Parmax Pharma Limited

Parmax Pharma Limited is currently managed by 3 directors, with 14 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.

Current Directors
Name Designation Appointment Date Tenure Status
Ami Shah Rajeshbhai Director 17 Jun 2018 8 Years 0 Months Current
Umang Alkesh Gosalia
Also directs: Malwin Pharma Private Limited
Managing Director 02 Jan 2016 10 Years 6 Months Current
Nikhil Sureshchandra Uchat Director 25 Apr 2023 3 Years 2 Months Current
View all directors

Financials of Parmax Pharma Limited FY 2026 filings available

Parmax Pharma Limited reported revenue of ₹12.11 Cr (down 57.06% YoY) for FY 2026.

Revenue · FY 2026
₹12.11 Cr ▼ 57.06%
Profit · FY 2026
-₹4.16 Cr ▼ 98.62%
Computed EBITDA · FY 2026
-₹3.59 Cr ▼ 1321.01%
Revenue₹ Cr · Standalone0102030FY 2019: ₹12 Cr12FY 2019FY 2020: ₹21 Cr · +74.3% YoY20.9+74.3%FY 2020FY 2021: ₹26 Cr · +25.2% YoY26.2+25.2%FY 2021FY 2022: ₹18 Cr · -30.4% YoY18.3-30.4%FY 2022FY 2023: ₹15 Cr · -15.5% YoY15.4-15.5%FY 2023FY 2024: ₹11 Cr · -28.3% YoY11.1-28.3%FY 2024FY 2025: ₹28 Cr · +155.2% YoY28.2+155.2%FY 2025FY 2026: ₹12 Cr · -57.1% YoY12.1-57.1%FY 2026
Net Profit₹ Cr · Standalone-6-4-202FY 2019: ₹0 Cr0.1FY 2019FY 2020: ₹0 Cr · +444.7% YoY0.4+444.7%FY 2020FY 2021: ₹1 Cr · +76% YoY0.8+76%FY 2021FY 2022: ₹0 Cr · -81.3% YoY0.1-81.3%FY 2022FY 2023: ₹0 Cr (loss) · -173.6% YoY-0.1FY 2023FY 2024: ₹6 Cr (loss) · -5425.6% YoY-5.8FY 2024FY 2025: ₹2 Cr (loss) · +63.6% YoY-2.1FY 2025FY 2026: ₹4 Cr (loss) · -98.6% YoY-4.2FY 2026
Quarterly Revenue₹ Cr · vs same quarter last year0510Q1'25: ₹8 Cr7.8Q1'25Q2'25: ₹9 Cr9.3Q2'25Q3'25: ₹6 Cr6.3Q3'25Q4'25: ₹5 Cr4.8Q4'25Q1'26: ₹2 Cr · -75.2% YoY1.9-75.2%Q1'26Q2'26: ₹3 Cr · -72.7% YoY2.5-72.7%Q2'26Q3'26: ₹4 Cr · -31.2% YoY4.3-31.2%Q3'26Q4'26: ₹3 Cr · -31.4% YoY3.3-31.4%Q4'26
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Revenue from Operations ₹12.11 Cr ₹28.2 Cr ₹11.05 Cr ₹15.42 Cr ₹18.25 Cr ₹26.2 Cr ₹20.93 Cr ₹12.01 Cr
Other Income ₹4.68 Lakh ₹3.96 Lakh ₹4.81 Lakh ₹3.97 Lakh ₹6.28 Lakh ₹8.89 Lakh ₹9.78 Lakh ₹4.82 Lakh
Total Income ₹12.16 Cr ₹28.24 Cr ₹11.1 Cr ₹15.46 Cr ₹18.31 Cr ₹26.29 Cr ₹21.03 Cr -
Cost of Materials Consumed ₹13.06 Cr ₹21.54 Cr ₹7.03 Cr ₹5.51 Cr ₹6.72 Cr ₹13.41 Cr ₹9.79 Cr ₹3.92 Cr
Purchases of Stock-in-Trade ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Changes in Inventories -₹3.18 Cr -₹25,000 ₹2.3 Lakh -₹2.1 Lakh -₹61,000 ₹2.31 Lakh ₹1.47 Cr ₹1.22 Cr
Employee Benefit Expense ₹2.5 Cr ₹2.99 Cr ₹2.91 Cr ₹2.8 Cr ₹3.46 Cr ₹3.54 Cr ₹2.91 Cr ₹2.08 Cr
Finance Costs ₹1.24 Cr ₹58.55 Lakh ₹62.17 Lakh ₹36.91 Lakh ₹38.58 Lakh ₹35.42 Lakh ₹12.74 Lakh ₹3.26 Lakh
Depreciation & Amortisation ₹1.01 Cr ₹1.03 Cr ₹1.71 Cr ₹1.88 Cr ₹1.93 Cr ₹1.94 Cr ₹1.01 Cr -
Other Expenses ₹3.36 Cr ₹3.43 Cr ₹4.46 Cr ₹4.88 Cr ₹5.52 Cr ₹5.82 Cr ₹4.99 Cr ₹3.68 Cr
Total Expenses ₹18 Cr ₹29.57 Cr ₹16.76 Cr ₹15.42 Cr ₹18.01 Cr ₹25.09 Cr ₹20.3 Cr ₹11.96 Cr
Profit Before Exceptional Items & Tax -₹5.85 Cr -₹1.32 Cr -₹5.66 Cr ₹4.61 Lakh ₹30.32 Lakh ₹1.21 Cr ₹73.06 Lakh -
Exceptional Items ₹0 -₹1.07 Cr ₹0 ₹0 ₹0 ₹0 ₹0 -
Profit Before Tax -₹5.85 Cr -₹2.4 Cr -₹5.66 Cr ₹4.61 Lakh ₹30.32 Lakh ₹1.21 Cr ₹73.06 Lakh ₹9.81 Lakh
Total Tax Expense -₹1.69 Cr -₹30.11 Lakh ₹9.47 Lakh ₹15.02 Lakh ₹16.18 Lakh ₹45.4 Lakh ₹30.2 Lakh ₹1.94 Lakh
Net Profit -₹4.16 Cr -₹2.09 Cr -₹5.75 Cr -₹10.41 Lakh ₹14.14 Lakh ₹75.44 Lakh ₹42.87 Lakh ₹7.87 Lakh
Other Comprehensive Income ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 -
Total Comprehensive Income -₹4.16 Cr -₹2.09 Cr -₹5.75 Cr -₹10.41 Lakh ₹14.14 Lakh ₹75.44 Lakh ₹42.87 Lakh -
EBITDA (computed) -₹3.59 Cr ₹29.42 Lakh -₹3.32 Cr ₹2.29 Cr ₹2.62 Cr ₹3.5 Cr ₹1.87 Cr -
Basic EPS ₹-11.12 ₹-5.60 ₹-15.37 ₹-0.28 ₹0.38 ₹2.02 ₹1.15 -
Diluted EPS ₹-11.12 ₹0.00 ₹-15.37 ₹-0.28 ₹0.38 ₹2.02 ₹1.15 -
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Total Assets ₹28.05 Cr ₹18.75 Cr ₹15.33 Cr ₹17.61 Cr ₹17.97 Cr ₹22.73 Cr ₹21.06 Lakh Cr ₹19.69 Cr
Non-current Assets ₹11.38 Cr ₹8.75 Cr ₹9.56 Cr ₹10.08 Cr ₹11.42 Cr ₹12.39 Cr ₹11.62 Lakh Cr ₹10.86 Cr
Current Assets ₹16.68 Cr ₹10 Cr ₹5.77 Cr ₹7.53 Cr ₹6.56 Cr ₹10.34 Cr ₹944,437 Cr ₹8.83 Cr
Property, Plant & Equipment ₹7.86 Cr ₹7.97 Cr ₹9.27 Cr ₹9.5 Cr ₹10.44 Cr ₹10.84 Cr ₹963,875 Cr -
Inventories ₹7.85 Cr ₹3.31 Cr ₹2.39 Cr ₹4.31 Cr ₹2.85 Cr ₹3.95 Cr ₹272,386 Cr ₹3.97 Cr
Trade Receivables ₹3.16 Cr ₹1.28 Cr ₹1.82 Cr ₹62.27 Lakh ₹67.69 Lakh ₹1.65 Cr ₹330,463 Cr -
Cash & Equivalents ₹64.97 Lakh ₹9.03 Lakh ₹5.1 Lakh ₹40.68 Lakh ₹1.05 Cr ₹2.55 Cr ₹176,749 Cr ₹1.57 Cr
Equity (Net Worth) -₹6.15 Cr -₹1.99 Cr ₹10.53 Lakh ₹5.86 Cr ₹5.96 Cr ₹5.82 Cr ₹506,399 Cr -
Equity Share Capital ₹4.45 Cr ₹4.45 Cr ₹4.45 Cr ₹4.45 Cr ₹4.45 Cr ₹4.45 Cr ₹445,115 Cr -
Borrowings (Non-current) ₹11.52 Cr ₹7.7 Cr ₹5.91 Cr ₹4.48 Cr ₹4.52 Cr ₹5.43 Cr ₹503,354 Cr -
Borrowings (Current) ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 -
Total Debt (computed) ₹11.52 Cr ₹7.7 Cr ₹5.91 Cr ₹4.48 Cr ₹4.52 Cr ₹5.43 Cr ₹503,354 Cr -
Current Liabilities ₹22.68 Cr ₹13.04 Cr ₹9.21 Cr ₹7.14 Cr ₹7.31 Cr ₹11.25 Cr ₹10.89 Lakh Cr ₹9.82 Cr
Total Liabilities ₹34.2 Cr ₹20.74 Cr ₹15.23 Cr ₹11.76 Cr ₹12.01 Cr ₹16.91 Cr ₹16 Lakh Cr -
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Operating Cash Flow -₹2.36 Cr -₹65.62 Lakh -₹19.62 Lakh ₹33.31 Lakh ₹74.93 Lakh
Investing Cash Flow -₹89.99 Lakh -₹70.14 Lakh -₹1.59 Cr -₹93.64 Lakh -₹1.53 Cr
Financing Cash Flow ₹3.81 Cr ₹1.4 Cr ₹1.43 Cr -₹4.42 Lakh -₹91 Lakh
Capital Expenditure ₹89.99 Lakh ₹70.14 Lakh ₹1.59 Cr ₹93.64 Lakh ₹0
Free Cash Flow (computed) -₹3.26 Cr -₹1.36 Cr -₹1.78 Cr -₹60.33 Lakh ₹74.93 Lakh
Dividends Paid ₹0 ₹0 ₹0 ₹0 ₹0
Net Change in Cash ₹55.95 Lakh ₹3.95 Lakh -₹35.57 Lakh -₹64.75 Lakh -₹1.69 Cr
The cash-flow statement became part of the exchange results-filing format in FY2022 - earlier years were not filed and are hidden.
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25
Revenue from Operations ₹3.31 Cr ₹4.33 Cr ₹2.53 Cr ₹1.94 Cr ₹4.83 Cr ₹6.28 Cr ₹9.28 Cr ₹7.82 Cr
Other Income ₹2.59 Lakh ₹72,000 ₹70,000 ₹67,000 -₹9.77 Lakh ₹1.27 Lakh ₹11.65 Lakh ₹80,100
Total Income ₹3.34 Cr ₹4.33 Cr ₹2.54 Cr ₹1.95 Cr ₹4.73 Cr ₹6.3 Cr ₹9.39 Cr ₹7.82 Cr
Cost of Materials Consumed ₹6.41 Cr ₹3.13 Cr ₹2.68 Cr ₹84.97 Lakh ₹2.96 Cr ₹4.97 Cr ₹7.44 Cr ₹6.17 Cr
Purchases of Stock-in-Trade ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Changes in Inventories -₹3.15 Cr -₹2.85 Lakh -₹12.26 Lakh ₹12.26 Lakh ₹74.82 Lakh -₹41.07 Lakh -₹3.15 Lakh -₹30.86 Lakh
Employee Benefit Expense ₹42.2 Lakh ₹78.42 Lakh ₹65.94 Lakh ₹63.15 Lakh ₹57.49 Lakh ₹84.38 Lakh ₹82.12 Lakh ₹74.85 Lakh
Finance Costs ₹49.63 Lakh ₹27.53 Lakh ₹24 Lakh ₹28.01 Lakh ₹23.77 Lakh ₹10.64 Lakh ₹12.89 Lakh ₹11.26 Lakh
Depreciation & Amortisation ₹24.98 Lakh ₹26.67 Lakh ₹25.58 Lakh ₹24.12 Lakh -₹17.7 Lakh ₹40.91 Lakh ₹40.34 Lakh ₹39.62 Lakh
Other Expenses ₹1.19 Cr ₹63.95 Lakh ₹90.55 Lakh ₹58.84 Lakh ₹1.11 Cr ₹77.63 Lakh ₹85.3 Lakh ₹68.93 Lakh
Total Expenses ₹5.61 Cr ₹5.06 Cr ₹4.62 Cr ₹2.71 Cr ₹5.45 Cr ₹6.69 Cr ₹9.61 Cr ₹7.81 Cr
Profit Before Exceptional Items & Tax -₹2.27 Cr -₹73.2 Lakh -₹2.08 Cr -₹76.45 Lakh -₹72.4 Lakh -₹39.45 Lakh -₹21.7 Lakh ₹1.23 Lakh
Exceptional Items ₹0 ₹0 ₹0 ₹0 -₹1.07 Cr ₹0 ₹0 ₹0
Profit Before Tax -₹2.27 Cr -₹73.2 Lakh -₹2.08 Cr -₹76.45 Lakh -₹1.8 Cr -₹39.45 Lakh -₹21.7 Lakh ₹1.23 Lakh
Total Tax Expense -₹1.69 Cr ₹0 ₹0 ₹0 -₹30.11 Lakh ₹0 ₹0 ₹0
Net Profit -₹58.44 Lakh -₹73.2 Lakh -₹2.08 Cr -₹76.45 Lakh -₹1.49 Cr -₹39.45 Lakh -₹21.7 Lakh ₹1.23 Lakh
Other Comprehensive Income ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Total Comprehensive Income -₹58.44 Lakh -₹73.2 Lakh -₹2.08 Cr -₹76.45 Lakh -₹1.49 Cr -₹39.45 Lakh -₹21.7 Lakh ₹1.23 Lakh
EBITDA (computed) -₹1.52 Cr -₹19 Lakh -₹1.58 Cr -₹24.32 Lakh -₹66.33 Lakh ₹12.1 Lakh ₹31.52 Lakh ₹52.12 Lakh
Basic EPS ₹-1.56 ₹-1.96 ₹-5.56 ₹-2.04 ₹-4.00 ₹-1.05 ₹-0.58 ₹0.03
Diluted EPS ₹-1.56 ₹-1.96 ₹-5.56 ₹0.00 ₹0.00 ₹0.00 ₹-0.58 ₹0.03
Latest 8 quarters shown.
Want more history and ratios?
You're viewing the latest exchange-filed financials for Parmax Pharma Limited. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Shareholding Pattern of Parmax Pharma Limited

As per the shareholding pattern filed with BSE for the quarter ended Mar 2026, promoters hold 30.80%, retail and other public shareholders hold 69.20% of Parmax Pharma Limited. The company had 2,388 shareholders on record.

Promoters: 30.80%Retail & Others: 69.20%
Mar 2026
QUARTER
30.80% Promoters
69.20% Retail & Others
Promoter holding - history
Now 30.80% · Mar 2026High 30.83% · Mar 2024Low 30.80% · Jun 2023
29%29.8%30.5%31.3%32%Jun 2023Dec 2023Jun 2024Dec 2024Jun 2025Dec 2025Jun 2023: 30.80%Sep 2023: 30.80%Dec 2023: 30.80%Mar 2024: 30.83%Jun 2024: 30.80%Sep 2024: 30.80%Dec 2024: 30.80%Mar 2025: 30.80%Jun 2025: 30.80%Sep 2025: 30.80%Dec 2025: 30.80%Mar 2026: 30.80%30.83%30.80%30.80%
Shareholding trend - last 6 quarters
Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Promoters30.80%30.80%30.80%30.80%30.80%30.80%
Public69.20%69.20%69.20%69.20%69.20%69.20%
Shareholding history - year on year (as at 31 March)
Mar 2026Mar 2025Mar 2024
Promoters30.80%30.80%30.83%
Public69.20%69.20%69.17%
Promoter change (YoY, %pts)+0.00-0.03-

Charges & Borrowings of Parmax Pharma Limited

Open charges
₹8.4 Cr
Satisfied charges
₹14.96 Cr
Breakdown by lending institutions
Others₹8.40 Cr
Latest charge details
DateLenderAmountStatus
17 Apr 2025 Others ₹8.4 Cr Open
31 May 2023 Others ₹6.72 Cr Satisfied
08 Feb 2019 Hdfc Bank Limited ₹1.12 Cr Satisfied
16 Oct 2018 Hdfc Bank Limited ₹6.85 Cr Satisfied
28 Jul 2017 Hdfc Bank Limited ₹26.7 Lakh Satisfied

Total charge records: 5 View all charges

Employees and EPFO Compliance at Parmax Pharma Limited

Parmax Pharma Limited has a workforce of 9 employees as of Apr 08, 2024.

Employee count
9
Active EPFO establishments
1
Employee growth
-64%
Premium access

Employee and EPFO history for Parmax Pharma Limited

Monthly headcount, contribution history, establishment records, and filing compliance require an active report plan.

  • Monthly headcount
  • PF contributions
  • ECR filing status
  • Establishment history

Verified entity values are shown only after access is granted.

GST Compliance of Parmax Pharma Limited

Premium access

GST registrations and filing compliance for Parmax Pharma Limited

State-wise registrations, return filing status, HSN and SAC details, and jurisdiction records require an active report plan.

  • GSTIN registrations
  • State-wise filing status
  • HSN and SAC details
  • Tax jurisdiction records

Verified entity values are shown only after access is granted.

Credit Ratings, Litigation & Regulatory Alerts for Parmax Pharma Limited

Premium access

Credit ratings, litigation, and regulatory alerts for Parmax Pharma Limited

Agency ratings, court records, regulatory events, and entity-specific compliance alerts require an active report plan.

  • Rating history
  • Court and tribunal cases
  • Regulatory alerts
  • Director-linked violations

Verified entity values are shown only after access is granted.

MSME Payment Delays by Parmax Pharma Limited

Premium access

MSME payment history for Parmax Pharma Limited

Amounts outstanding to micro and small suppliers, delay reasons, and MSME-1 filing history require an active report plan.

  • Outstanding amounts
  • Delay periods and reasons
  • MSME-1 filing history
  • Vendor payment signals

Verified entity values are shown only after access is granted.

Subsidiaries & Group Companies of Parmax Pharma Limited

Premium access

Corporate group structure for Parmax Pharma Limited

Parent, subsidiary, associate, joint venture, and ownership records require an active report plan.

  • Parent company
  • Subsidiaries and ownership
  • Associates and joint ventures
  • Entity investments

Verified entity values are shown only after access is granted.

MCA Filings & Documents of Parmax Pharma Limited

Premium access

MCA filings and documents for Parmax Pharma Limited

Official forms, annual returns, financial statements, charge filings, and document dates require an active report plan.

  • Incorporation documents
  • Annual returns and statements
  • Charge filings
  • Complete filing index

Verified entity values are shown only after access is granted.

Recent Activity on Parmax Pharma Limited

Charges
17 Apr 2025
A charge with Others amounted to Rs. 8.40 Cr with Charge ID 101092470 was registered on 17 Apr 2025.
Charges
07 Apr 2025
A charge registered on 31 May 2023 via Charge ID 100775935 with Others was fully satisfied on 07 Apr 2025.
Activity
30 Sep 2024
Parmax Pharma Limited last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records.
Activity
31 Mar 2024
Parmax Pharma Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Ahmedabad.
Charges
10 Nov 2023
A charge with Others of Rs. 6.72 Cr registered on 31 May 2023 with Charge ID 100775935 was modified on 10 Nov 2023.
Charges
16 Oct 2023
A charge registered on 08 Feb 2019 via Charge ID 100240259 with Hdfc Bank Limited was fully satisfied on 16 Oct 2023.

Recent News on Parmax Pharma Limited

Frequently Asked Questions about Parmax Pharma Limited

Parmax Pharma Limited is an active public limited company in the pharma sector based in Hadamtala, Gujarat, India. It was incorporated on 02 November 1994 (32+ years old) and is registered under CIN L24231GJ1994PLC023504. Listed on BSE: 540359. The company has 9 employees.

Parmax Pharma Limited reported revenue of ₹12.11 Cr for FY 2026 (down 57.06% YoY) based on standalone BSE filings.

The current directors of Parmax Pharma Limited are:

The primary industry of Parmax Pharma Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.

Yes. Parmax Pharma Limited is listed on BSE with code 540359.

Parmax Pharma Limited can be reached at the registered office: Plot No. 20 Survey No. 52 Rajkot – Gondal National Highway No. 27, Hadamtala, Gujarat, India – 360311, or through the website parmaxpharma.com.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - sourced from MCA, SEBI and RBI filings.

Subscription plans available